The impact of onabotulinumtoxinA on severe headache days: PREEMPT 56-week pooled analysis

BACKGROUND: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders b...

Descripción completa

Detalles Bibliográficos
Autores principales: Matharu, Manjit, Halker, Rashmi, Pozo-Rosich, Patricia, DeGryse, Ronald, Manack Adams, Aubrey, Aurora, Sheena K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539058/
https://www.ncbi.nlm.nih.gov/pubmed/28766236
http://dx.doi.org/10.1186/s10194-017-0784-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539058/
https://www.ncbi.nlm.nih.gov/pubmed/28766236
http://dx.doi.org/10.1186/s10194-017-0784-4

Ejemplares similares